Taysha Gene Therapies (TSHA) Operating Expenses (2020 - 2026)

Taysha Gene Therapies has reported Operating Expenses for 7 years, with the latest figure at $43.5 million in Q1 2026.

• Quarterly Operating Expenses rose 83.31% year-over-year to $43.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $140.0 million (up 46.21% YoY) and the FY2025 annual result came in at $120.3 million, up 20.52% from the prior year.
• Operating Expenses advanced to $43.5 million in Q1 2026 per TSHA's latest filing, from $33.8 million in the prior quarter.
• Over five years, Operating Expenses peaked at $56.5 million in Q4 2022 and troughed at $19.8 million in Q4 2023.
• A 5-year average of $30.4 million and a median of $27.7 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2023 and 2026: Operating Expenses slumped 64.85% in 2023, then surged 83.31% in 2026.
• Over 5 years, Operating Expenses stood at $56.5 million in 2022, then plunged by 64.85% to $19.8 million in 2023, then grew by 10.6% to $22.0 million in 2024, then surged by 53.89% to $33.8 million in 2025, then rose by 28.71% to $43.5 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $43.5 million, $33.8 million, and $34.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.